Peptide Comparison

    Sermorelin vs Tesamorelin

    Sermorelin and tesamorelin are both GHRH analogs, but tesamorelin is FDA-approved for visceral fat reduction in HIV-associated lipodystrophy, while sermorelin is used primarily in age-management protocols.

    Sermorelin

    Sermorelin is a synthetic analog of the first 29 amino acids of GHRH, previously FDA-approved for growth hormone deficiency diagnosis and treatment. It stimulates natural GH production from the pituitary gland and is widely used in age-management protocols for its favorable safety profile.

    Sermorelin Clinical Reference

    Tesamorelin

    Tesamorelin is an FDA-approved synthetic GHRH analog indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It stimulates physiological growth hormone secretion and has demonstrated significant visceral adipose tissue reduction in clinical trials.

    Tesamorelin Clinical Reference

    Key Differences

    Category
    Sermorelin
    Tesamorelin
    FDA status
    Previously FDA-approved (now off-market as branded drug).
    FDA-approved as Egrifta for HIV-associated lipodystrophy.
    Primary clinical use
    Anti-aging, sleep, GH optimization.
    Visceral adipose tissue (VAT) reduction.
    Structure
    First 29 amino acids of GHRH.
    Stabilized GHRH analog with extended half-life.

    This comparison is informational and reflects content from TruthTides clinical reference documentation. It does not constitute medical advice. Only three peptides on TruthTides — semaglutide, tirzepatide, and tesamorelin — carry FDA approvals; many others are compounded or off-label. Consult a qualified physician before starting any peptide therapy.